Martin N Stienen1, Johanna M Visser-Meily2, Tom A Schweizer3, Daniel Hänggi4, R Loch Macdonald3, Mervyn D I Vergouwen5. 1. Department of Neurosurgery, UniversitätsSpital Zürich, Clinical Neuroscience Center, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland. mnstienen@gmail.com. 2. Department of Rehabilitation, Physical Therapy Science and Sports, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands. 3. Division of Neurosurgery, Department of Surgery, St. Michael's Hospital, Labatt Family Centre of Excellence in Brain Injury and Trauma Research, Keenan Research Centre for Biomedical Research and Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Canada. 4. Department of Neurosurgery, University Medical Center Mannheim, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. 5. Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract
INTRODUCTION: In studies on aneurysmal subarachnoid hemorrhage (SAH), substantial variability exists in the use and timing of outcomes and endpoints, which complicates interpretation and comparison of results between studies. The aim of the National Institute of Health/National Institute of Neurological Disorders and Stroke/National Library of Medicine Unruptured Intracranial Aneurysm (UIA) and SAH common data elements (CDE) Project was to provide a common structure for future UIA and SAH research. METHODS: This article summarizes the recommendations of the UIA and SAH CDE Outcomes and Endpoints subgroup, which consisted of an international and multidisciplinary ad hoc panel of experts in clinical outcomes after SAH. Consensus recommendations were developed by review of previously published CDEs for other neurological diseases and the SAH literature. Recommendations for CDEs were classified by priority into "Core," "Supplemental-Highly Recommended," "Supplemental," and "Exploratory." RESULTS: The subgroup identified over 50 outcomes measures and template case report forms (CRFs) to be included as part of the UIA and SAH CDE recommendations. None was classified as "Core". The modified Rankin Scale score and Montreal Cognitive Assessment were considered the preferred outcomes and classified as Supplemental-Highly Recommended. Death, Glasgow Outcome Scale score, and Glasgow Outcome Scale-extended were classified as Supplemental. All other outcome measures were categorized as "Exploratory". We propose outcome assessment at 3 months and at 12 months for studies interested in long-term outcomes. We give recommendations for standardized dichotomization. CONCLUSION: The recommended outcome measures and CRFs have been distilled from a broad pool of potentially useful CDEs, scales, instruments, and endpoints. The adherence to these recommendations will facilitate the comparison of results across studies and meta-analyses of individual patient data.
INTRODUCTION: In studies on aneurysmal subarachnoid hemorrhage (SAH), substantial variability exists in the use and timing of outcomes and endpoints, which complicates interpretation and comparison of results between studies. The aim of the National Institute of Health/National Institute of Neurological Disorders and Stroke/National Library of Medicine Unruptured Intracranial Aneurysm (UIA) and SAH common data elements (CDE) Project was to provide a common structure for future UIA and SAH research. METHODS: This article summarizes the recommendations of the UIA and SAH CDE Outcomes and Endpoints subgroup, which consisted of an international and multidisciplinary ad hoc panel of experts in clinical outcomes after SAH. Consensus recommendations were developed by review of previously published CDEs for other neurological diseases and the SAH literature. Recommendations for CDEs were classified by priority into "Core," "Supplemental-Highly Recommended," "Supplemental," and "Exploratory." RESULTS: The subgroup identified over 50 outcomes measures and template case report forms (CRFs) to be included as part of the UIA and SAH CDE recommendations. None was classified as "Core". The modified Rankin Scale score and Montreal Cognitive Assessment were considered the preferred outcomes and classified as Supplemental-Highly Recommended. Death, Glasgow Outcome Scale score, and Glasgow Outcome Scale-extended were classified as Supplemental. All other outcome measures were categorized as "Exploratory". We propose outcome assessment at 3 months and at 12 months for studies interested in long-term outcomes. We give recommendations for standardized dichotomization. CONCLUSION: The recommended outcome measures and CRFs have been distilled from a broad pool of potentially useful CDEs, scales, instruments, and endpoints. The adherence to these recommendations will facilitate the comparison of results across studies and meta-analyses of individual patient data.
Entities:
Keywords:
Aneurysm; Clinical studies; Common data elements; Data coding; Data collection; Endpoints; Hemorrhagic stroke; MoCA; Modified Rankin Scale; Montreal Cognitive Assessment; Outcomes; Standardization; Subarachnoid hemorrhage; mRS
Authors: Andrew Molyneux; Richard Kerr; Irene Stratton; Peter Sandercock; Mike Clarke; Julia Shrimpton; Rury Holman Journal: Lancet Date: 2002-10-26 Impact factor: 79.321
Authors: S A Mayer; K T Kreiter; D Copeland; G L Bernardini; J E Bates; S Peery; J Claassen; Y E Du; E S Connolly Journal: Neurology Date: 2002-12-10 Impact factor: 9.910
Authors: Kurt T Kreiter; Daphne Copeland; Gary L Bernardini; Joseph E Bates; Shelley Peery; Jan Claassen; Y Evelyn Du; Yaakov Stern; E Sander Connolly; Stephan A Mayer Journal: Stroke Date: 2002-01 Impact factor: 7.914
Authors: Jari Siironen; Seppo Juvela; Joona Varis; Matti Porras; Kristiina Poussa; Sorella Ilveskero; Juha Hernesniemi; Riitta Lassila Journal: J Neurosurg Date: 2003-12 Impact factor: 5.115
Authors: Joseph R Geraghty; Melissa N Lara-Angulo; Milen Spegar; Jenna Reeh; Fernando D Testai Journal: J Stroke Cerebrovasc Dis Date: 2020-06-20 Impact factor: 2.136
Authors: Jose I Suarez; Muniza K Sheikh; R Loch Macdonald; Sepideh Amin-Hanjani; Robert D Brown; Airton Leonardo de Oliveira Manoel; Colin P Derdeyn; Nima Etminan; Emanuela Keller; Peter D Leroux; Stephan A Mayer; Akio Morita; Gabriel Rinkel; Daniel Rufennacht; Martin N Stienen; James Torner; Mervyn D I Vergouwen; George K C Wong Journal: Neurocrit Care Date: 2019-06 Impact factor: 3.210
Authors: Ilari M Rautalin; Martina Sebök; Menno R Germans; Miikka Korja; Noemi Dannecker; Olivia Zindel-Geisseler; Peter Brugger; Luca Regli; Martin N Stienen Journal: Neurol Sci Date: 2019-12-04 Impact factor: 3.307
Authors: Alexander Hammer; Frank Erbguth; Matthias Hohenhaus; Christian M Hammer; Hannes Lücking; Markus Gesslein; Monika Killer-Oberpfalzer; Hans-Herbert Steiner; Hendrik Janssen Journal: BMC Neurol Date: 2021-01-19 Impact factor: 2.474
Authors: Jens Witsch; Bob Siegerink; Christian H Nolte; Maximilian Sprügel; Thorsten Steiner; Matthias Endres; Hagen B Huttner Journal: Neurol Res Pract Date: 2021-05-03
Authors: Shaurya Taran; Vatsal Trivedi; Jeffrey M Singh; Shane W English; Victoria A McCredie Journal: Neurocrit Care Date: 2020-06 Impact factor: 3.210
Authors: Peter Y M Woo; Joanna W K Ho; Natalie M W Ko; Ronald P T Li; Leo Jian; Alberto C H Chu; Marco C L Kwan; Yung Chan; Alain K S Wong; Hoi-Tung Wong; Kwong-Yau Chan; John C K Kwok Journal: BMC Neurol Date: 2020-11-03 Impact factor: 2.474